Skip to main content
ADIA
OTC Life Sciences

Adia Nutrition Reports Worsening Losses, Going Concern Warning, and Ineffective Controls; Omits Recent Positive News

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$0.17
Mkt Cap
0
52W Low
$0.018
52W High
$0.278
Market data snapshot near publication time

summarizeSummary

Adia Nutrition's Q1 2026 report reveals deepening financial distress, a going concern warning, and ineffective internal controls, while conspicuously omitting recent positive news, raising significant transparency concerns.


check_boxKey Events

  • Going Concern Warning Reiterated

    The company continues to express "substantial doubt" about its ability to continue as a going concern due to ongoing losses and cash burn, a concern previously noted in its 10-K filed on March 31, 2026.

  • Worsening Financial Performance

    Net loss increased to $162,525 for the three months ended March 31, 2026, compared to $116,219 in the prior year. Cash used in operations also rose to $55,037 from $31,175, indicating an accelerating cash burn despite revenue growth.

  • Ineffective Internal Controls

    Management concluded that disclosure controls and procedures were not effective as of December 31, 2025, highlighting a critical governance and compliance issue.

  • Increased Related-Party Debt

    The company's line of credit from its CEO increased to $723,656 from $600,000, indicating continued reliance on insider funding to sustain operations.


auto_awesomeAnalysis

Adia Nutrition's latest quarterly report highlights a deteriorating financial state with increased net losses and cash burn, alongside a reiterated "going concern" warning and ineffective internal controls. Critically, the filing states no material subsequent events occurred through May 13, 2026, directly contradicting recent news releases about a strategic partnership and pivotal clinical study. This raises serious concerns about the company's financial transparency and reporting integrity, especially given its heavy reliance on related-party debt for operations.

At the time of this filing, ADIA was trading at $0.17 on OTC in the Life Sciences sector. The 52-week trading range was $0.02 to $0.28. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ADIA - Latest Insights

ADIA
May 14, 2026, 9:32 PM EDT
Filing Type: 10-Q
Importance Score:
9
ADIA
May 05, 2026, 10:08 AM EDT
Source: TMX Newsfile
Importance Score:
8
ADIA
Apr 08, 2026, 8:30 AM EDT
Source: TMX Newsfile
Importance Score:
8
ADIA
Mar 31, 2026, 3:49 PM EDT
Filing Type: 10-K
Importance Score:
9